Bagel, Jerry, April W. Armstrong, Richard B. Warren, Kim A. Papp, Diamant Thaçi, Alan Menter, Jennifer Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, and Christopher EM Griffiths. “Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy by Prior Treatment in the Phase 3 POETYK PSO-1 Trial”. SKIN The Journal of Cutaneous Medicine 7, no. 2 (March 13, 2023): s117. Accessed April 26, 2024. https://jofskin.org/index.php/skin/article/view/1969.